NCT05871398 is a Phase 3 clinical trial of Tegoprazan in Laryngopharyngeal Reflux Disease, sponsored by Pusan National University Hospital.

Who is sponsoring NCT05871398?

NCT05871398 is sponsored by Pusan National University Hospital.

What drugs are being tested in NCT05871398?

Interventions in NCT05871398: Tegoprazan, Placebo.

What condition does NCT05871398 study?

NCT05871398 studies Laryngopharyngeal Reflux Disease.

Is NCT05871398 still recruiting?

NCT05871398 is currently completed. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT05871398

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease

Completed Phase 3 Last updated 1 June 2023

What this trial tests

Phase 3 trial testing Tegoprazan in Laryngopharyngeal Reflux Disease in 36 participants. Completed in 28 February 2023.

Timeline

1 October 2019

Primary endpoint
30 December 2021

28 February 2023

Quick facts

Lead sponsor	Pusan National University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	36
Start date	1 October 2019
Primary completion	30 December 2021
Estimated completion	28 February 2023
Sites	1 location across South Korea

Drugs / interventions tested

Tegoprazan — full drug profile →
Placebo

Conditions studied

Laryngopharyngeal Reflux Disease — all drugs for Laryngopharyngeal Reflux Disease →

Sponsor

Pusan National University Hospital

Who can join

19 and older, any sex, with Laryngopharyngeal Reflux Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. The investigators aimed to evaluate whether tegoprazan would be more effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux disease (LPRD). Methods: This double-blind, randomized, placebo-controlled trial randomly assigned 35 patients suffering LPRD symptom to two groups: Tegoprazan50mg once daily and placebo. The primary end point was complete resolution rate of LPRD symptoms after 8-week medication, and the secondary endpoints were complete resolution rate of LPRD symptoms after 4-week medication, change of reflux symptom index (RSI) and reflux finding score (RFS) from baseline at 4- and 8-week medication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study.
Jeon HK, Kim GH, Cheon YI, Shin SC, et al · · 2023 · cited 5× · PMID 37834761 · DOI 10.3390/jcm12196116

Verify or expand the search:

Other trials of Tegoprazan

Trials testing the same drug.

NCT07277712 — A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT06743243 — Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia · Phase 4 · enrolling by invitation
NCT06977841 — Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial · NA · completed
NCT06894992 — Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment · NA · recruiting
NCT07242456 — Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID fo · Phase 2, PHASE3 · recruiting

Other Pusan National University Hospital trials

Trials by the same sponsor.

NCT07073365 — Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The · Phase 2 · recruiting
NCT06878495 — Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease · NA · not yet recruiting
NCT06805123 — Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection · NA · recruiting
NCT06752395 — Cryobiopsy Vs. Forceps Biopsy for Peripheral Pulmonary Lesions · NA · enrolling by invitation
NCT07455552 — Comparison of Telemedicine-based and Home-based Inspiratory Muscle Training After Lung Resection in High-risk Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05871398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pusan National University Hospital
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05871398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing